Heart Pump Correction: Abiomed Issues Correction for Automated Impella Controllers
FDA announces a correction for certain Automated Impella Controllers (AIC) due to potential safety issues that could delay or loss of hemodynamic support. This is a medical device recall/correction, not directly related to med-spa or aesthetics clinics. However, if your clinic uses Impella heart pumps (unlikely), action is required. For most med-spas, no action needed.
Aforeworn detected this change in the Med-Spa & Aesthetics Clinics space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Med-spa and aesthetics clinics that use Automated Impella Controllers (extremely rare; typically only hospitals or cardiac centers). should confirm how it applies to their specific situation before acting. There is a time constraint attached: As soon as possible if affected; otherwise N/A.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Med-Spa & Aesthetics Clinics continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Abiomed issued a correction for certain AIC units requiring hardware updates to address safety concerns.
Who it affects
Med-spa and aesthetics clinics that use Automated Impella Controllers (extremely rare; typically only hospitals or cardiac centers).
What you must do
If you have an Impella system, contact Abiomed for hardware update. Otherwise, no action.
Deadline
As soon as possible if affected; otherwise N/A.
Never miss a change like this again
Aforeworn watches Med-Spa & Aesthetics Clinics around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Med-Spa & Aesthetics Clinics
- FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
- Accolade Pacemaker Devices by Boston Scientific and Potential Need for Early Device Replacement - FDA Safety Communication
- Disruptions in Availability of Breast Biopsy Needles - Letter to Health Care Providers
- UPDATE: Hintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure: FDA Safety Communication
- The Safer Affordable Fuel-Efficient (SAFE) Vehicles Rule for Model Years 2021-2026 Passenger Cars and Light Trucks